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Preterm birth complications are the leading cause of child death worldwide and a top 
global health priority. Among the survivors, the risk of life-long disabilities is high, including 
cerebral palsy and impairment of movement, cognition, and behavior. Understanding the 
molecular mechanisms of preterm brain injuries is at the core of future healthcare 
improvements. Glutamate excitotoxicity is a key mechanism in preterm brain injury, 
whereby the accumulation of extracellular glutamate damages the delicate immature 
oligodendrocytes and neurons, leading to the typical patterns of injury seen in the 
periventricular white matter. Glutamate excitotoxicity is thought to be  induced by an 
interaction between environmental triggers of injury in the perinatal period, particularly 
cerebral hypoxia-ischemia and infection/inflammation, and developmental and genetic 
vulnerabilities. To avoid extracellular build-up of glutamate, the brain relies on rapid uptake 
by sodium-dependent glutamate transporters. Astrocytic excitatory amino acid transporter 
2 (EAAT2) is responsible for up to 95% of glutamate clearance, and several lines of 
evidence suggest that it is essential for brain functioning. While in the adult EAAT2 is 
predominantly expressed by astrocytes, EAAT2 is transiently upregulated in the immature 
oligodendrocytes and selected neuronal populations during mid-late gestation, at the 
peak time for preterm brain injury. This developmental upregulation may interact with 
perinatal hypoxia-ischemia and infection/inflammation and contribute to the selective 
vulnerability of the immature oligodendrocytes and neurons in the preterm brain. Disruption 
of EAAT2 may involve not only altered expression but also impaired function with reversal 
of transport direction. Importantly, elevated EAAT2 levels have been found in the reactive 
astrocytes and macrophages of human infant post-mortem brains with severe white 
matter injury (cystic periventricular leukomalacia), potentially suggesting an adaptive 
mechanism against excitotoxicity. Interestingly, EAAT2 is suppressed in animal models of 
acute hypoxic-ischemic brain injury at term, pointing to an important and complex role in 
newborn brain injuries. Enhancement of EAAT2 expression and transport function is 
gathering attention as a potential therapeutic approach for a variety of adult disorders 
and awaits exploration in the context of the preterm brain injuries.
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GLOBAL SIGNIFICANCE OF PRETERM 
BRAIN INJURIES
Perinatal care has advanced considerably in the last century 
and has improved survival of many vulnerable newborns, 
including those born preterm. The World Health Organization 
estimates that 15 million newborns (1  in 10 live births) are 
born preterm (<37  weeks of gestation) worldwide each year 
(World Health Organization, 2012). Despite global improvements, 
the United Nations Millennium Development Goal to reduce 
childhood mortality by two-thirds in 2015 was not achieved 
globally (United Nations, 2015) and 2.7 million children died 
in the first month of life worldwide in 2015. Of these babies, 
over 900,000 died due to preterm birth complications – the 
leading cause of death of newborns and children under 5 years 
old (Liu et  al., 2016). For the newborns who survive, the 
multi-organ damage can result in life-long disabilities. Globally, 
preterm birth complications represent the fourth leading cause 
of years of “healthy” life lost due to disability (i.e., over 102,000 
DALYs), above causes such as diarrheal diseases, diabetes, and 
HIV (World Health Organization, 2016).
Prematurity is a major risk factor for cerebral palsy, “a group 
of permanent disorders of the development of movement and 
posture, causing activity limitation, that are attributed to 
non-progressive disturbances that occurred in the developing 
fetal or infant brain” (Bax et al., 2005; Rosenbaum et al., 2007). 
Cerebral palsy is the most common physical disability in 
childhood and is a heterogeneous diagnosis, including different 
clinical types and brain imaging patterns, comorbidities, and 
multiple causes (Stanley et  al., 2000; Locatelli et  al., 2010; 
MacLennan et  al., 2015). Preterm birth is clearly an important 
risk factor and risk is 30 times higher in children born before 
33 weeks of gestation than in those born at term (Stanley, 1992; 
Himpens et  al., 2008; Beaino et  al., 2010; Mercier et  al., 2010; 
Tronnes et al., 2014; MacLennan et al., 2015; Stavsky et al., 2017). 
A recent meta-analysis estimated an increase in prevalence 
from 1.4/1,000 live births in children born at term (>36  weeks 
of gestation) to 6.8/1,000 live births in moderate to late preterm 
(32–36  weeks of gestation), rising to 43.2/1,000 live births in 
very preterm (28–31  weeks of gestation) and 82.3/1,000 live 
births in extremely preterm infants (<28  weeks of gestation) 
(Oskoui et  al., 2013; Hirvonen et  al., 2014). More than a third 
of the extremely preterm children with cerebral palsy are unable 
to walk (Moore et al., 2012), and many have multiple disabilities, 
which may further limit independence and quality of life 
(Litt et  al., 2005; Glass et  al., 2008, 2015; Soria-Pastor et  al., 
2008; Anderson et  al., 2011; Moore et  al., 2012). A systematic 
review of international cerebral palsy registers in high-income 
settings highlighted the extent of these comorbidities: around 
three quarters of children with cerebral palsy suffer from chronic 
pain; approximately half have intellectual disabilities (IQ, executive 
function, language ability); around a quarter have active epilepsy, 
hip dislocation, bladder control problems, behavioral problems, 
sleep disorders, and/or speech impairment; 11 and 4% have severe 
vision and hearing impairment, respectively (Novak et al., 2012). 
There are less data from low-income settings, but it is likely 
that comorbidities, as well as mortality, are higher (Khandaker 
et al., 2015). Preterm birth complications impose a considerable 
economic burden on the public sector, which was estimated 
around £2.9 billion in England and Wales in 2006 (Mangham 
et  al., 2009). While administration of magnesium sulfate as a 
preventative treatment to the mother during preterm labor 
has been shown to reduce risk of cerebral palsy by a third 
in very preterm infants (Doyle et  al., 2009), no postnatal 
therapy currently exists for preterm brain injury. This is a 
global health priority as the increase in both preterm birth 
and survival rates has not been matched by a decrease in 
long-term disability (Wilson-Costello et  al., 2005).
NEUROIMAGING AND 
NEUROPATHOLOGY OF PRETERM 
BRAIN INJURIES
Preterm birth is associated with smaller brain volumes (Peterson 
et  al., 2003; Inder et  al., 2005; Srinivasan et  al., 2007) as 
well as motor, cognitive, and behavioral problems at school 
age (Peterson et al., 2000, 2003; Abernethy et al., 2004; Nosarti 
et  al., 2005; Gimenez et  al., 2006; Anderson and Doyle, 2008; 
Kesler et  al., 2008; Aarnoudse-Moens et  al., 2009; Delobel-
Ayoub et  al., 2009; Soria-Pastor et  al., 2009; Anderson et  al., 
2017). Progress in neuroimaging techniques has been key in 
linking childhood neurodevelopmental outcomes to perinatal 
brain injuries and in advancing our knowledge of the underlying 
neuropathology (Volpe, 2009c; Back, 2017). Both MRI-defined 
preterm white matter injury (periventricular leukomalacia) 
and preterm birth are predictive of cerebral palsy (Constantinou 
et  al., 2007; Spittle et  al., 2008, 2009, 2018; Duerden et  al., 
2013). In a large European population study of cerebral palsy, 
white matter injury was the most common feature found in 
over 40% of the children (Bax et al., 2006). Originally, cranial 
ultrasound could only detect the most severe cystic type of 
white matter injury (cystic periventricular leukomalacia), 
characterized by focal macroscopic cysts of necrotic tissue 
in the deep white matter (de Vries et  al., 1992) and highly 
predictive of cerebral palsy (Leviton and Paneth, 1990; De 
Vries et  al., 2004; Serdaroglu et  al., 2004; Fetters and Huang, 
2007). Necrotic white matter injury can also evolve into 
microscopic glial scars, which may not be visible with traditional 
ultrasound. These are a more common type of injury and 
are sufficient to cause a loss in brain volume (Volpe, 2009c; 
Volpe et al., 2011). With the development of MRI techniques, 
a diffuse type of white matter injury has increasingly been 
recognized in the form of diffuse disturbances of myelination 
in the central white matter. This has emerged as the predominant 
type of white matter injury, accounting for over 90% of 
periventricular leukomalacia cases, as well as the predominant 
type of preterm brain injury altogether, occurring in 50% 
preterm newborns (Volpe, 2008). Importantly, while rates of 
the more severe cystic form have declined to less than 5% 
with advances in perinatal care, this has not been reflected 
for the diffuse forms (Maalouf et  al., 2001; Counsell et  al., 
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2003; Inder et al., 2003; Miller et al., 2003; Back et al., 2007b; 
Volpe, 2008). These could be  seen as different manifestations 
of an “encephalopathy of prematurity” (Volpe, 2009c) or even 
as distinct pathologies (Back and Rosenberg, 2014). In the 
last two decades, advanced MRI techniques have highlighted 
that injury is not limited to the white matter but it extends 
to the deep grey matter, cortex, and cerebellum, all of which 
contribute to the volume loss (Counsell and Boardman, 2005; 
Ball et  al., 2012). The cerebellum is gathering attention as a 
key target of injury. This region grows rapidly at the peak 
time for preterm birth and damage in the form of infarction, 
atrophy, and poor growth has been reported as common in 
very preterm infants developing cerebral palsy and long-term 
motor, cognitive, and behavioral impairment (Mercuri et  al., 
1997; Abraham et  al., 2001; Bodensteiner and Johnsen, 2005; 
Johnsen et  al., 2005; Limperopoulos et  al., 2005a,b, 2007; 
Nosarti et al., 2008; Parker et al., 2008; Lawrence et al., 2014). 
Indeed, there is a relationship between cerebellar volume loss 
and white matter injury, pointing to the existence of a common 
insult, such as hypoxia-ischemia and infection/inflammation, 
which are known to damage the developing cerebellum 
(Shah et  al., 2006; Volpe, 2009b; Hutton et  al., 2014).
Disentangling the spatial and temporal contributions of 
infection/inflammation and hypoxia-ischemia will be  key in 
understanding brain injuries across the perinatal spectrum. 
For example, while white matter injury is typical of the preterm 
newborn, it may be  present in a subset of newborns born at 
term who experienced in utero hypoxic-ischemic insults (e.g., 
placental insufficiencies) (Mallard et al., 1998; Rees et al., 1998; 
Zhu et al., 2016). Indeed, newborns born at term with hypoxic-
ischemic encephalopathy are also at high risk and up to 40% 
develop cerebral palsy (Gluckman et al., 2005; Shankaran et al., 
2005; Azzopardi et  al., 2009; Simbruner et  al., 2010; Jacobs 
et  al., 2011). Investigating the molecular basis for divergence 
between term and preterm injuries is paramount for development 
of age-appropriate pharmacological therapies.
PATHOGENESIS OF PRETERM  
BRAIN INJURIES
Brain injury is thought to be  more common in preterm than 
term newborns for several reasons, including developmental 
and genetic vulnerabilities and differential exposure to adverse 
perinatal environments. A considerable body of in vitro and 
in vivo evidence points two potential triggers of injury, hypoxia-
ischemia, and infection/inflammation (Volpe, 2008, 2009a; 
Deng, 2010; Volpe et  al., 2011; Back and Rosenberg, 2014; 
Back, 2017). These insults are thought to interact in the 
vulnerable immature brain and converge onto three downstream 
mechanisms of injury: inflammation, glutamate excitotoxicity, 
and ultimately free radical attack, which directly damages 
cell components as well as triggering delayed cell death by 
apoptosis. Severity and temporal profile of hypoxia-ischemia 
and infection/inflammation, degree of brain maturity, 
comorbidities, sex, and genetic background may all contribute 
to individual differences in pathogenesis, clinical presentation, 
and individual susceptibility to injury. We  will review the 
role of developmental vulnerabilities, infection/inflammation, 
and hypoxia-ischemia and bring the focus on the common 
downstream mechanism of glutamate excitotoxicity. We  will 
then review the evidence linking glutamate transport to 
excitotoxic preterm brain injuries and highlight the current 
evidence supporting excitatory amino acid transporter 2 
(EAAT2) as a potential therapeutic target.
Developmental Vulnerability
The brain undergoes rapid and critical developmental events 
during the peak time of premature brain injury (24–32 weeks), 
including neuronal migration, growth of axons and dendrites, 
synaptogenesis, development of the vascular system, and 
myelination. Interference with these natural trajectories 
determines selective cellular and regional vulnerabilities and 
may redirect subsequent development. Among their functions, 
oligodendrocytes are responsible for laying the highly specialized 
myelin membrane around axons and are therefore key for 
the development of the white matter. Myelination begins before 
birth and peaks in the first 2 years of postnatal life, with 
the intracortical fibers of the cortex being myelinated in the 
third decade. The process of myelination requires that 
oligodendrocytes first proliferate and develop into mature 
oligodendrocytes and then depose myelin around axons (Volpe, 
2008). Around the peak time of preterm brain injury 
(28–32  weeks of gestation), the pre-oligodendrocyte stage still 
represents the majority of the oligodendrial pool in the very 
preterm brain (Iida et  al., 1995; Back et  al., 2001). 
Pre-oligodendrocytes are more vulnerable than mature 
oligodendrocytes to hypoxia-ischemia, infection/inflammation, 
oxidative damage, and ultimately cell death (Back et  al., 1998, 
2002, 2005, 2007b; Fern and Moller, 2000; Baud et  al., 2004; 
Fragoso et  al., 2004; Segovia et  al., 2008; Volpe et  al., 2011). 
Indeed, a unique feature of periventricular white matter injury 
is an arrest in the development of oligodendrocytes at the 
pre-oligodendrocyte stage, leading to the abnormal myelination 
patterns typically seen through MRI (Back et al., 2007b; Volpe 
et  al., 2011). More severe necrotic injury extends to all the 
cell components, leading to cysts and exacerbating myelin 
injury via focal axonal degeneration (Laptook, 2016; Back, 
2017). Concurrent developmental vulnerabilities include the 
limited ability of the immature brain to synthesize appropriate 
amounts of growth factors needed for brain development and 
self-protection, and an immature immune system, potentially 
promoting an excessive and sustained inflammatory response 
(Gilles et  al., 2018).
Environmental Triggers of Injury: Hypoxia/
Ischemia and Infection/Inflammation
Alongside the intrinsic developmental vulnerability of the 
immature brain, the preterm newborn is exposed to a range 
of potentially harmful exposures in the perinatal period. 
Supported by mounting experimental and epidemiological 
evidence, perinatal infection/inflammation leading to an overly 
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intense inflammatory response, or a “cytokine storm”, has 
increasingly been recognized as a major risk factor not only 
for preterm birth but also for preterm white matter injury 
and long-term neurodisabilities (Yoon et al., 1996, 1997, 2000; 
Baud et  al., 1999; Duggan et  al., 2001; Dollner et  al., 2002; 
Heep et  al., 2003; Kaukola et  al., 2004, 2006; Ellison et  al., 
2005; Bi et  al., 2014). The preterm brain is often exposed 
to inflammation early during fetal development (e.g., maternal 
infections and chorioamnionitis) and usually for prolonged 
periods during postnatal life in the neonatal intensive care 
environment (e.g., neonatal infections, inflammatory 
comorbidities such as necrotizing enterocolitis), during critical 
phases of myelination and brain plasticity (Murphy et  al., 
1995; Grether and Nelson, 1997; Verma et al., 1997; Alexander 
et al., 1998; Dammann and Leviton, 1998, 2000, 2004; O’Shea 
et  al., 1998; Leviton et  al., 1999; Wu and Colford, 2000; 
Dammann et  al., 2002; Rezaie and Dean, 2002; Stoll et  al., 
2002; Wu, 2002; Schlapbach et al., 2011; Hagberg et al., 2015; 
Anblagan et al., 2016). A combination of multiple inflammatory 
hits, antenatally and postnatally, has been shown to increase 
risk of brain injury and disability compared to single hits 
(Korzeniewski et  al., 2014; van der Burg et  al., 2016; Yanni 
et  al., 2017). Indeed, pharmacological interventions targeting 
inflammation may have translational potential based on 
preclinical studies (Hagberg et  al., 2015).
The role of hypoxia-ischemia in preterm brain injury is 
more controversial. In term newborns with hypoxic-ischemic 
encephalopathy, defined and acute hypoxic-ischemic events 
before or during birth (e.g., placental abruption, cord occlusion, 
and uterine rupture) are usually recognized by the clinician 
and represent the first step of a diagnosis of hypoxic-ischemic 
encephalopathy, aided by objective clinical and neuroimaging 
criteria. In the preterm newborn, a sentinel event is rarely 
recognized, and hypoxia-ischemia is generally assumed to have 
a more complex temporal profile, with intermittent or 
chronic nature (Laptook, 2016; Ohshima et  al., 2016). 
However, it remains challenging to determine the individual 
contribution of hypoxia-ischemia among several coexistent 
factors, such as infection/inflammation, growth restriction, or 
hyperoxia (Gopagondanahalli et  al., 2016). Physiologically, it 
is conceivable that the preterm brain is vulnerable to hypoxia-
ischemia due to the anatomical and functional immaturity 
of the periventricular vasculature, which would make the 
periventricular white matter vulnerable to minor drops in 
cerebral perfusion (Takashima and Tanaka, 1978; Lou et  al., 
1979; De Reuck, 1984; Altman et  al., 1988; Pryds, 1991; 
Miyawaki et al., 1998; Inage et al., 2000; Volpe, 2008; Laptook, 
2016). The periventricular white matter has lower basal blood 
flow compared to grey matter regions in both humans (Greisen, 
1986; Pryds et  al., 1990) and the preterm fetal sheep 
(Szymonowicz et  al., 1988; Gleason et  al., 1989; Riddle et  al., 
2006). Further drops in blood flow are common in sick 
premature infants with respiratory disease due to lung 
immaturity (Soul et  al., 2007). Mechanical ventilation may 
contribute to ischemia due to the vasoconstrictive effect of 
the induced cumulative hypocarbia (Shankaran et  al., 2006). 
Perinatal hypoxic-ischemic episodes are also likely to play a 
key role, including ongoing placental pathologies, an overlapping 
risk factor for intrauterine growth restriction, low birthweight, 
and preterm birth. A meta-analysis recently reported an 
association between preterm brain injury and perinatal risk 
factors related to hypoxia-ischemia, including oligohydramnios, 
acidemia, low Apgar scores, apnea, respiratory distress syndrome, 
and seizures (Huang et  al., 2017). However, the link between 
regional differences in blood flow and vulnerability to severe 
white matter injury is not consistent, and even in moderate 
ischemia, some regions of white matter are spared. This suggests 
that ischemia is necessary but not sufficient in isolation (Riddle 
et  al., 2006; McClure et  al., 2008; Back, 2017). Indeed, it has 
been suggested that more consistent evidence is needed to 
ascertain the specific role of hypoxic and ischemic events in 
preterm brain injury altogether and that future research should 
take into account contributions and interactions with other 
biological processes, including infection/inflammation and 
developmental vulnerability (Gilles et  al., 2018). Importantly, 
the impact of hypoxia-ischemia on the cerebellum is also 
emerging, as shown by reports of volume loss and death of 
Purkinje cells and Bergmann glia in term newborns with 
hypoxic-ischemic encephalopathy and mid-late gestation fetal 
sheep exposed to asphyxia (Rees et  al., 1997; Inage et  al., 
1998; Castillo-Melendez et al., 2004; Biran et al., 2012; Hutton 
et al., 2014). In an established mouse model of chronic hypoxia 
recapitulating perinatal brain injuries, damage to the cerebellum 
was reported in terms of a significant loss of GABAergic 
interneurons and a delay in dendritic arborization of 
Purkinje cells, followed by motor impairment and cerebellar 
learning deficits (Chahboune et al., 2009; Zonouzi et al., 2015; 
Sathyanesan et  al., 2018).
Several experimental studies have shown that hypoxia-
ischemia and infection/inflammation lead to worse brain 
and behavioral outcomes when they interact, and insults 
that are individually insufficient to cause injury can lead 
to injury when combined (Dommergues et  al., 2000; Eklind 
et al., 2001; Lehnardt et al., 2003; Ikeda et al., 2004; Larouche 
et  al., 2005; Favrais et  al., 2007; Wang et  al., 2007, 2009, 
2010; Aden et  al., 2010; van Tilborg et  al., 2018). This has 
led to the multiple hit hypothesis of preterm brain injury, 
whereby a mild first event sensitizes the brain to subsequent 
insults (Leviton et  al., 2013; Van Steenwinckel et  al., 2014; 
Barnett et al., 2018). The current hypothesis is that hypoxia-
ischemia triggers an inflammatory response per se. This 
additional endogenous response combined with the inflammation 
triggered by infection leads to a pro-inflammatory “cytokine 
storm,” which is not matched by upregulation of anti-
inflammatory cytokines and neurotrophic factors. This in 
turn sensitizes the brain to hypoxic-ischemic injury by 
enhancing glutamate excitotoxicity and damaging the blood-
brain barrier (Hagberg et  al., 2015). Tertiary mechanisms 
of injury, mediated by epigenetic modifications, may 
sustain  the sensitization in the long term and interfere with 
remodeling and repair mechanisms (Dammann, 2007;  
Fleiss and Gressens, 2012).
A substantial body of experimental evidence suggests that 
glutamate excitotoxicity triggered by hypoxia-ischemia and/or 
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infection/inflammation plays a key role in the pathogenesis of 
preterm white matter injury (Hagberg et al., 2002; Johnston, 2005; 
Volpe, 2008; Deng, 2010; Volpe et  al., 2011).
GLUTAMATE EXCITOTOXICITY IN THE 
PRETERM BRAIN
Glutamate Homeostasis and Dysregulation
Glutamate is the main excitatory neurotransmitter in the 
mammalian brain (Meldrum, 2000). It is essential for brain 
function, orchestrating not only fast excitatory 
neurotransmission but also long-lasting neuronal changes 
necessary for memory, learning, and cognition. It is also 
fundamental during brain development, due to its role in 
regulating formation and elimination of synapses, as well 
as neuronal migration, proliferation, and viability. Glutamate 
is abundant inside the brain cells, and most neurons and 
glial cells have glutamate receptors distributed across most 
cellular elements, highlighting the importance of glutamatergic 
systems for normal function (Curtis and Johnston, 1974; 
Watkins and Evans, 1981; Bliss and Collingridge, 1993; 
Newcomer et  al., 2000; Platt, 2007). Stimulation of a 
glutamatergic neuron results in Ca2+-dependent release of 
glutamate in the synapse by vesicular exocytosis. Extracellular 
glutamate binds to and activates post-synaptic ionotropic 
(NMDA, AMPA, and kainate receptors) and metabotropic 
(mGluR) glutamate receptors, stimulating the post-synaptic 
neurons via Ca2+ or Na+ influx and inducing intracellular 
signaling cascades that lead to physiological cellular responses, 
such as regulation of transcription factors and DNA replication 
(Nicholls and Attwell, 1990; Danbolt, 2001).
Glutamatergic transmission is terminated when glutamate 
transporters, expressed predominantly by astrocytes, slowly take 
up glutamate from the synaptic space (30 glutamate molecules 
per second at Vmax) (Otis and Kavanaugh, 2000; Bergles et  al., 
2002; Grewer and Rauen, 2005; Takahashi et  al., 2015). In the 
preterm brain, glutamate transporters are also expressed by 
immature neurons and oligodendrocytes, although their significance 
is controversial, as reviewed below. In astrocytes, glutamate is 
converted to glutamine via glutamine synthetase. Glutamine is 
shuttled back into the pre-synaptic neuron, where it is converted 
into glutamate via glutaminase (Figure 1). The glutamate-glutamine 
cycle is not essential for supplying glutamate for neuronal release 
but is needed for normal glutamatergic transmission (Danbolt, 
2001; Takahashi et  al., 2015; Danbolt et  al., 2016).
The ubiquity of glutamate is a double-edged sword: when 
homeostasis is disrupted, glutamate can turn into a potent 
neurotoxin. If the concentration of glutamate in the extracellular 
space rises above physiological levels, post-synaptic glutamate 
receptors are overactivated. This excessive activation, or 
excitotoxicity, leads to cell death via activation of suicide cell 
programs (apoptosis) (Danbolt, 2001; Sattler and Tymianski, 
2001) (Figure 1). Since it was first proposed in the late 1960s 
(Olney, 1969), the concept of glutamate excitotoxicity has been 
implicated in several adult disorders, both acute (e.g., ischemic 
stroke and traumatic brain injury) and chronic (e.g., amyotrophic 
lateral sclerosis, Alzheimer’s, Parkinson’s, major depression, and 
addiction) (Doble, 1999; Takahashi et  al., 2015). Consistently, 
injection of glutamate agonists into the cortex, striatum, and 
A B
FIGURE 1 | The glutamate/glutamine cycle in (A) physiological conditions and (B) excitotoxic conditions in the immature brain. (A) In the mature healthy brain, 
glutamate is released by exocytosis from the pre-synaptic neuronal terminal into the synapse (1), and it binds to post-synaptic ionotropic (NMDA, AMPA, and kainate 
receptors) and metabotropic (mGluR) glutamate receptors, inducing Ca2+-mediated signaling cascades that result in cellular responses (2). Extracellular glutamate is 
taken up primarily by astroglial EAAT2 (3) and converted to glutamine (4), which is shuttled back to the pre-synaptic terminal via glutamine transporters (5). Here, 
glutamine is converted back to glutamate (6). (B) During excitotoxicity, a combination of increased neuronal release and decreased astroglial uptake lead to a rise of 
extracellular glutamate levels, leading to overactivation of the post-synaptic glutamate receptors, Ca2+ overload, and activation of apoptotic pathways. Reversal of 
transport of astroglial transporters may also contribute to the accumulation of extracellular glutamate. In the immature brain, upregulation of the glutamate 
transporters in underdeveloped neurons and oligodendrocytes may contribute to their selective vulnerability.
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periventricular white matter of newborn rodents, rabbits, and 
kittens produces patterns of perinatal brain injuries similar to 
those seen in humans (McDonald et  al., 1988; Innocenti and 
Berbel, 1991a,b; Marret et  al., 1995; Gressens et  al., 1996; 
Acarin et  al., 1999; Follett et  al., 2000). On the other hand, 
pharmacological inhibition of glutamate receptors before or 
immediately after an hypoxic-ischemic insult is neuroprotective 
in both preterm (Follett et  al., 2004; Manning et  al., 2008) 
and term (Hagberg et  al., 1994; Follett et  al., 2000) brain 
injuries. Indeed, one of the mechanisms through which 
magnesium sulfate is thought to exert neuroprotection is by 
preventing excitotoxic damage through NMDA receptor blockade 
(Lingam and Robertson, 2018).
In vivo Evidence of Glutamate Excitotoxicity
Evidence of in vivo disturbance of glutamate signaling has 
been produced for animal models of hypoxic-ischemic brain 
injury. In a rat model of mild white matter injury near term, 
a rise in extracellular glutamate is observed in the acute phase 
after hypoxia-ischemia, with oligodendrocytes and axons 
representing the major sources of extracellular glutamate and 
astrocytes failing to take up excess glutamate (Back et  al., 
2007a). Similarly, repeated umbilical cord occlusion in the 
near-term fetal sheep causes periventricular white matter injury, 
the extent of which correlates with extracellular local glutamate 
levels (Loeliger et  al., 2003). Notably, the largest increase in 
glutamate occurred over the hours after the insult, a delayed 
increase that suggested impaired glutamate transport. In a piglet 
model of hypoxic-ischemic encephalopathy at term, glutamate 
levels in the basal ganglia were shown to change in two phases: 
an early increase in the first 6  hours was followed by transient 
and slight recovery by 12  hours, possibly due to the self-
protective glutamate transport mechanisms and conversion to 
glutamine in astrocytes; a further increase occurred after a 
day, possibly through cells bursting due to reperfusion injury 
and reversal of glutamate transport in the late stages of disease 
(Dang et  al., 2017). In humans, elevated glutamate levels have 
been reported in the cerebrospinal fluid and basal ganglia of 
asphyxiated newborns (Riikonen et  al., 1992; Hagberg et  al., 
1993). Moreover, elevated glutamine levels have been found 
in MRI-defined punctate necrotic white matter lesions (Wisnowski 
et al., 2013). Glutamate is taken up into astrocytes for conversion 
into glutamine and shuttling back to neurons. The finding of 
elevated glutamine rather than glutamate may be  due at least 
in part to the temporal lag between insult and measurement. 
An important limitation of in vivo glutamate measurements 
in preterm newborns is that the peak window of glutamate 
changes is probably missed, because magnetic resonance 
measurements are likely to be  carried out long after the initial 
insults in newborns that have already become sick. As such, 
these findings suggest that disrupted glutamate homeostasis 
persists in the subacute phase in moderate necrotic white matter 
injury. Although a relatively small subset of the newborns 
with punctate lesions also had evidence of cysts, no studies 
to date have measured glutamatergic metabolism specifically 
in newborns with severe cystic white matter injury.
Glutamate Excitotoxicity Following 
Hypoxia-Ischemia
Glutamate homeostasis can be  disrupted by an acute hypoxic-
ischemic event, and the phases of the subsequent excitotoxic 
injury are well described. During the primary energy failure, 
oxygen and blood deprivation lead to impairment of ATP 
production due to failure of oxidative phosphorylation. Astrocytes, 
with their unique oxidative capacity and ability to upregulate 
ATP production, are central to maintaining energy metabolism 
during the first stage of ischemia (Dienel and Hertz, 2005). 
Impairment of the ATP-dependent Na+/K+ pumps leads to loss 
of the electrochemical gradient across the cell membrane. If the 
insult is severe, some cells may die at this early stage via necrosis, 
due to influx of ions and water, cell swelling, and bursting. 
Within hours, the necrotic injury due to severe energy failure 
leads to death of all cellular elements and develops into the 
white matter cysts (Back, 2017). Depolarization of the cell 
membrane activates Ca2+ channels in the pre-synaptic terminal, 
triggering vesicular release of glutamate in the synapse. In 
astrocytes, hypoxia-ischemia leads to a failure in the astrocytic 
glutamate uptake system, which also relies on Na+/K+ gradients. 
The combination of increased synaptic release and reduced 
astrocytic uptake leads to accumulation of glutamate in the 
synaptic space and overactivation of post-synaptic ionotropic and 
metabotropic glutamate receptors (Volpe, 2008). The subsequent 
intracellular Ca2+ influx triggers activation of phospholipases, 
endonucleases, proteases, and nitric oxide synthase, with 
degradation of cellular and extracellular structures, and generation 
of harmful free radicals and reactive oxygen and nitrogen species. 
Glutamate leaking outside the synapse activates extrasynaptic 
NMDA receptors, which, contrarily to the pro-survival action 
of synaptic NMDA receptors, promotes excitotoxic cell death 
even further (Parsons and Raymond, 2014). This excitotoxic-
oxidative cascade eventually leads to cell damage or death via 
necrosis, apoptosis, and autophagy in the secondary phase of 
injury (Olney, 1969; Benveniste et  al., 1984; McDonald and 
Johnston, 1990; Choi, 1992; Thornton et  al., 2012; Back, 2017; 
Descloux et  al., 2018) (Figure 1).
Glutamate Excitotoxicity Following 
Inflammation
In preterm brain injury, comorbidities stimulating inflammation 
are thought to contribute to disruption of glutamate homeostasis 
and potentiation of excitotoxicity. TNFα, for example, is one of 
the most studied cytokines and is emerging as a key link between 
inflammation and glutamate excitotoxicity (Olmos and Llado, 
2014). TNFα has both neuroprotective and neurotoxic effects 
depending on the different signaling pathways activated by the 
different receptors. In fact, pharmacological inhibition or genetic 
deletion after a combined inflammatory and excitotoxic insult 
is neuroprotective (Aden et  al., 2010; Kendall et  al., 2011), but 
knocking out TNFα receptors in the mouse increases susceptibility 
to hypoxic-ischemic injury (Bruce et al., 1996). TNFα potentiates 
glutamate excitotoxicity in vitro via complex and interacting 
mechanisms involving crosstalk between neurons and glial cells 
and leading to vicious cycles of glutamate and cytokine release. 
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In neurons, TNFα increases the excitatory strength at the synapse 
by increasing cell surface expression of glutamate receptors and 
their permeability to Ca2+, while also decreasing expression of 
inhibitory GABAA receptors (Olmos and Llado, 2014). In microglia, 
TNFα stimulates autocrine release of TNFα and glutamate by 
upregulating glutaminase and from hemichannels of gap junctions 
(Takeuchi et al., 2006). In astrocytes, TNFα stimulates glutamate 
release via prostaglandin E2 and exacerbates impairment of 
glutamate transport (Bezzi et  al., 1998). Cheung et  al. (1998) 
suggested that glutamate concentration may be key in determining 
the pathways of cell death, with higher glutamate concentrations 
preferentially triggering necrosis and lower concentrations leading 
to apoptosis. Either way, even transient excess of glutamate can 
start a number of events that ultimately cause death or damage 
of vulnerable cell populations (Ottersen et  al., 1996).
Glutamate Excitotoxicity and Perinatal 
Brain Injuries
The patterns of excitotoxic injury tend to be  different in the 
preterm and term brain. Experimental evidence suggests that 
the main cellular target of excitotoxic injury in the preterm 
brain is pre-oligodendrocytes (Volpe et  al., 2011). Glutamate 
is highly toxic to pre-oligodendrocytes in cell culture and leads 
to cell death via free radical attack (Oka et  al., 1993). The 
white matter in the rat is much more vulnerable to hypoxia-
ischemia at preterm-equivalent age, when pre-oligodendrocytes 
are predominant, than at term-equivalent age, when mature 
oligodendrocytes are the major form (Back et  al., 2002; Craig 
et al., 2003; Dean et al., 2011). Indeed, the patterns of hypoxic-
ischemic white matter injury seem to be  determined primarily 
by the timing of appearance (Buser et  al., 2010) and spatial 
distribution (Riddle et al., 2006) of pre-oligodendrocytes rather 
than severity of ischemia itself. Pre-oligodendrocytes are strikingly 
more vulnerable than immature neurons of the cortex and 
caudate nucleus in moderate global ischemia in the preterm 
fetal sheep (Dean et al., 2013; McClendon et al., 2014). Immature 
neurons are also vulnerable, as NMDA receptors are functionally 
upregulated, more permeable to calcium and less sensitive to 
magnesium block (Jantzie et  al., 2015).
In physiological conditions, the abundance of glutamate 
receptors in the white matter is key during early neuronal 
development, contributing to rapid growth and myelination. 
However, their abundance also confers increased vulnerability 
in excitotoxic conditions (Kaindl et  al., 2009). Indeed, the 
selective vulnerability of subplate neurons compared to cortical 
neurons observed in a preterm model of hypoxia-ischemia 
has been suggested to originate from an increase of glutamate 
receptors in these neurons associated with early maturation 
(McQuillen et  al., 2003). Similarly, it has been suggested that 
selective vulnerability of the deep grey matter and sensorimotor 
cortex in term hypoxic-ischemic encephalopathy could be related 
to peaking NMDA receptor expression and proximity to 
developing glutamatergic circuits (Rocha-Ferreira and Hristova, 
2016). As such, developmental expression of key glutamatergic 
genes in the grey and white matter may contribute to the 
different patterns of excitotoxic injury (Volpe, 2008).
Overall, the potential sources of extracellular glutamate in 
the white matter include pre-oligodendrocytes, astrocytes, 
neurons, ependymal cells, and cells of the choroid plexus (Back 
and Rosenberg, 2014). While therapies targeting excitotoxicity 
have so far mostly focused on glutamate receptor blockade, 
targeting glutamate transport is gathering interest as a potential 
avenue for neuroprotection by counteracting glutamate 
accumulation in the first place (Tilleux and Hermans, 2007; 
Kim et  al., 2011; Fontana, 2015; Takahashi et  al., 2015).
GLUTAMATE TRANSPORT: FOCUS  
ON EAAT2/GLT-1
Maintaining the baseline extracellular glutamate concentrations 
in the nanomolar range is essential to avoid extracellular 
glutamate build-up. The brain has no known enzymatic 
mechanism to metabolize glutamate in the extracellular space, 
and simple diffusion over short distances is thought to bring 
only a minor contribution. Hence, the brain relies substantially 
on intracellular glutamate uptake, and astrocytes provide by 
far the largest contribution to preventing excitotoxicity through 
expression of glutamate transporters (Danbolt, 2001; Tzingounis 
and Wadiche, 2007; Vandenberg and Ryan, 2013). Given their 
crucial role, it is not surprising that expression of astrocytic 
glutamate transporters is constitutively high (Zhou and Danbolt, 
2013). Crosstalk between neurons and glia relies on tightly 
controlled extracellular glutamate homeostasis, and it is becoming 
increasingly evident that neuron-glia interactions are central 
to both the kinetics of glutamatergic synaptic activity in 
physiological (Fontana, 2015) and excitotoxic conditions 
(Carmignoto, 2000). Glutamate is released by astrocytes in 
immature rat optic nerve in ischemia in vitro (Wilke et  al., 
2004). Moreover, glutamate transport has been observed in 
immature axons (Arranz et  al., 2008), and impairment has 
been reported in pre-oligodendrocytes during hypoxia-ischemia, 
providing a potential mechanism of excitotoxic vulnerability 
(Oka et  al., 1993; Domercq et  al., 1999; Fern and Moller, 
2000; Deng et  al., 2003; Desilva et  al., 2007, 2009). The 
importance of glutamate transport to the integrity of 
oligodendrocytes and white matter is supported by evidence 
of extensive excitotoxic injury in oligodendrocytes and axons 
with experimental inhibition of glutamate transport in the optic 
nerve in vivo (Domercq et  al., 2005).
The five members of the excitatory amino acid transporter 
(EAAT) family carry out most of the glutamate clearance in 
the central nervous system (Anderson and Swanson, 2000), 
especially EAAT1 (SLC1A3, rodent orthologue Glast) and EAAT2 
(SLC1A2, rodent orthologue Glt-1) (Bristol and Rothstein, 1996). 
EAAT2 is the major glutamate transporter in the forebrain, 
except in the cerebellum, circumventricular organs, and retina, 
where EAAT1 is prevalent. In physiological conditions, both 
EAAT1 and EAAT2 are expressed predominantly by astrocytes 
and localized to the cellular membrane in the adult brain 
(Danbolt, 2001; Roberts et  al., 2014; Takahashi et  al., 2015). 
The high concentration (1  mg/g rat brain tissue), ubiquity 
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(1% of total CNS protein in the adult brain), and high degree 
of conservation across mammalian species are all indications 
of physiological importance of EAAT2/Glt-1 (Danbolt, 2001; 
Fontana, 2015; Danbolt et al., 2016). Unsurprisingly, it is expressed 
at high density near glutamatergic synapses in developing 
hippocampal astrocytes, with density and vicinity increasing 
with neuronal activity (Benediktsson et  al., 2012). This 
transmembrane transporter carries out glutamate uptake through 
a high affinity energy-dependent process driven by Na+ and 
K+ gradients. Specifically, glutamate and aspartate are 
co-transported inside the brain cells with 3 Na+ and 1 H+ for 
the antiport of 1  K+. EAAT2 is also a selective anion channel, 
transporting Cl− anions during intermediate conformations, 
uncoupled from the flux of glutamate (Fontana, 2015).
Several lines of evidence support the central role of EAAT2 
expression/function in maintaining extracellular glutamate 
homeostasis. Pharmacological inhibition of glutamate transport, 
including EAAT2, leads to rapid extracellular glutamate increase 
in vitro (Jabaudon et  al., 1999) and extended post-synaptic 
activation mediated by NMDA receptors (Lozovaya et al., 1999). 
Genetic deletion of Glt-1 via constitutive knockout in the 
mouse leads to lower body weight, seizures, acute cortical 
injury in the forebrain, and increased mortality from the second/
third postnatal week (Tanaka et  al., 1997). Brain tissue from 
this mouse shows much lower (5%) glutamate transport activity 
than wild-type, suggesting that Glt-1 is responsible for up to 
95% of glutamate transport. This is confirmed by the ability 
of Glt-1 antibodies to remove 90% of the transport activity 
in forebrain tissue (Haugeto et al., 1996). Other Glt-1 knockouts 
have confirmed the obvious phenotype, with lower life span, 
lower body and brain weight, mild loss of CA1 neurons in 
the hippocampus, and severe focal neuronal loss in layer II 
of the neocortex and focal gliosis (Kiryk et  al., 2008). A 
conditional knockout mouse with selective deletion of Glt-1 
reproduces this phenotype while ruling out developmental 
adaptations (Zhou et  al., 2014). Heterozygote knockouts, on 
the other hand, show halved concentrations of Glt-1, but no 
apparent morphological brain changes, despite an increased 
risk of traumatic spinal cord injury (Kiryk et  al., 2008; Lepore 
et  al., 2011). Inhibition with antisense oligonucleotides in vitro 
and in vivo induces a rise in extracellular glutamate, excitotoxic 
injury, and progressive paralysis (Rothstein et  al., 1996). On 
the other hand, selective overexpression in astrocytes is 
neuroprotective during ischemia (Chao et  al., 2010).
Studies of EAAT2 expression point to different patterns 
depending on cell type, region, developmental age, species, 
and methodology used (DeSilva et  al., 2012). In the adult rat, 
Glt-1 is expressed in the forebrain, especially in the hippocampus, 
cortex, striatum, and thalamus as well as in fibrous astrocytes 
in the white matter (Lehre et  al., 1995). The transporter is 
expressed predominantly by astrocytes but also pre-synaptic 
axon terminals in the rodent hippocampus and somatosensory 
cortex (Danbolt, 2001; Chen et  al., 2004; Furness et  al., 2008; 
Melone et  al., 2009; de Vivo et  al., 2010; Danbolt et  al., 2016). 
Neuronal EAAT2 represents no more than 10–20% total EAAT2 
(Furness et  al., 2008; Danbolt et  al., 2016), and while being 
implicated in adult neuropsychiatric disorders (O’Donovan 
et al., 2017), neuronal knockout barely affects total Glt-1 protein 
levels and mouse development (Petr et  al., 2015). Conversely, 
astrocytic knockout leads to a reduction of protein levels to 
a fifth in the forebrain, lower body weight and increased 
epilepsy and mortality.
Developmental Expression of EAAT2
The scenario may be  at least in part different in the preterm 
brain, where transient but more prominent neuronal and 
pre-oligodendrial expression is observed. During development, 
dynamic and species-specific changes in both cellular and 
regional expression have been observed, suggesting that 
glutamate transporters may be both regulated by and involved 
in brain development (e.g., participation in the development 
of the topographic organization). As expected, these changes 
in rodent Glt-1 expression correspond to changes in total 
glutamate uptake activity (Ullensvang et  al., 1997). Briefly, 
Glt-1 expression is low until after birth, except for a transient 
peak of expression in developing axons and oligodendrocytes 
around mid-late gestation. Glt-1 is expressed in vivo in rat 
pre-oligodendrocytes, whereas it is no longer detectable in 
mature oligodendrocytes (DeSilva et  al., 2009). Transient 
neuronal expression is also seen around mid-late gestation 
in the mouse (Sutherland et  al., 1996; Yamada et  al., 1998), 
rat (Furuta et  al., 1997), and sheep (Northington et  al., 1998). 
In the fetal rat, Glt-1 is expressed in the amygdala and 
hippocampus, as well as white matter tracts interconnecting 
neocortex, basal ganglia, and thalamus (Furuta et  al., 1997). 
In the fetal sheep, Glt-1 is found not only in white matter 
tracts but also in neuronal bodies and extended to the subplate, 
cranial nerve nuclei, basal ganglia, and cerebellar cortex, 
highlighting potential species differences in cellular expression 
during development (Furuta et  al., 1997; Northington et  al., 
1998, 1999). In the newborn rat at P1, Glt-1 levels are the 
highest in the spinal cord and moderate in the hippocampus 
and hypothalamus. Expression increases dramatically from the 
second postnatal week throughout the central nervous system, 
especially in the cortex, striatum, caudate nucleus, and 
hippocampus, reaching adult levels by weeks 4–5 (Rothstein 
et  al., 1994; Levy et  al., 1995; Shibata et  al., 1996; Sutherland 
et  al., 1996; Furuta et  al., 1997; Ullensvang et  al., 1997). 
Astrocyte selectivity is established in the postnatal period in 
rodents and around mid-late gestation in sheep (Furuta et  al., 
1997; Takasaki et al., 2008). Nonetheless, Glt-1 is still detected 
in immature axons at P14–17 (Arranz et  al., 2008). The 
significant developmental changes in Glt-1 after birth may 
explain why the Glt-1 knockout mice seem to develop normally 
for the first few weeks and develop seizures and brain injury 
during postnatal week 3, with many dying by week 4 
(Tanaka et  al., 1997; Takasaki et  al., 2008).
A limited number of studies have investigated developmental 
regulation of EAAT2  in humans. DeSilva et  al. (2012) found 
that, among EAAT1–3, expression of EAAT2 undergoes 
particularly prominent maturational changes in post-mortem 
cortex tissue of preterm and term newborns without neurological 
disease, all the way into childhood. Consistent with animal 
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studies, EAAT2 expression is generally low until birth and is 
limited to glia limitans, layer I-III fine astrocytes, and some 
neuron populations. EAAT2 was found not only in axons but 
also in the cell body and dendrites of certain neuron populations 
from as early as 23 gestational weeks up until term and, in 
some cases, until 8 postnatal months. These neuron populations 
are layer V pyramidal neurons, layer I neurons (putative Cajal-
Retzius cells), and subplate neurons (DeSilva et  al., 2012). A 
great proportion of these neuronal populations is glutamatergic, 
and it has been suggested that this transient neuronal EAAT2 
expression is critical for establishing and orchestrating excitatory 
transmission during maturation and migration of cortical 
neurons. Similarly, it could also provide the basis for selective 
vulnerability to premature excitotoxic injury due to expression 
of glutamate transporters, which may reverse transport and 
become sources of extracellular glutamate (Takasaki et al., 2008; 
DeSilva et  al., 2012), as discussed below. This is supported by 
evidence of selective vulnerability of layer V pyramidal neurons 
and subplate neurons in human and rat preterm white matter 
injury (McQuillen et  al., 2003; Andiman et  al., 2010). The 
same group reported EAAT2 expression in pre-oligodendrocytes 
in human fetal white matter at 32  weeks of gestation, during 
the peak time for premature brain injury, but not at 7  months 
old, consistent with rat studies (Desilva et  al., 2007). EAAT2 
expression appeared in the astrocytes of the developing cortex 
at 41 postconceptional weeks, increasing steeply in the first 
1.5  years (DeSilva et  al., 2012). Taken together, these findings 
suggest that the expression of EAAT2/Glt-1 undergoes substantial 
changes during development and that these changes may 
contribute to the selective vulnerability of cellular (e.g., immature 
oligodendrocytes and neurons) and regional (e.g., white matter 
tracts, hippocampus) targets in preterm brain injury.
EAAT2 and Preterm Brain Injury
Following severe energy failure, the dissipation of the 
transmembrane gradient impairs astrocytic EAAT2, which relies 
on transmembrane Na+/K+ gradients. This disruption may involve 
both quantity and quality of transport activity, i.e., it can manifest 
as decreased expression and/or impairment of glutamate transport 
function with establishment of reverse transport. Reverse transport 
has an outward direction and is driven by the transmembrane 
gradient of excitatory amino acids independently of ATP and 
Ca2+ (Nicholls and Attwell, 1990; Szatkowski et  al., 1990; Levi 
and Raiteri, 1993). In this scenario, glutamate transporters 
become themselves a major source of extracellular glutamate, 
potentially turning into key contributors of excitotoxic injury 
in any cells expressing them (Domingues et al., 2010) (Figure 1). 
While its significance to preterm brain injuries remains to 
be  explored, the importance of reverse transport is supported 
by evidence that ischemic cell death in the rat striatum can 
be  blocked by an inhibitor of reverse Glt-1 transport (Seki 
et  al., 1999). Moreover, knockout mice lacking Glt-1 are more 
vulnerable to neuronal death after a short, severe episode of 
ischemia than wild-type mice, suggesting that Glt-1 is essential 
for neuroprotection when ischemia is acute; on the other hand, 
wild-type mice expressing Glt-1 are more vulnerable to neuronal 
death than mice lacking Glt-1 during extended, chronic ischemia, 
suggesting that Glt-1 (via reverse transport) becomes neurotoxic 
when ischemia is prolonged (Mitani and Tanaka, 2003).
Consistent with impairment of glutamate transport, a decrease 
in glutamate uptake is seen in the hippocampus of rat pups 
exposed to intrauterine hypoxia following caesarean delivery 
(Frizzo et  al., 2010) and in the cortex, basal ganglia and 
thalamus of newborn piglets exposed to hypoxia (Jantzie et al., 
2010). Loss of Glt-1 expression and/or function has been 
reported in astrocyte cultures during hypoxia (Dallas et  al., 
2007) as well as in the adult rat cortex and hippocampus after 
ischemia (Torp et  al., 1995; Rao et  al., 2001a,b). In a small 
study of term-equivalent rats, astrocytic Glt-1 was suppressed 
in the initial 12  hours in the ischemic core of both the 
hippocampus and the neocortex, recovered after 48 hours only 
in the hippocampus, followed by astrogliosis at 72  hours 
(Fukamachi et al., 2001). In a piglet model of hypoxic-ischemic 
encephalopathy at term, canonical suppression of Glt-1 in 
astrocytes of the striatum and hippocampus was accompanied 
by upregulation in neurons of the striatum (Martin et  al., 
1997b; Danbolt, 2001; Pow et  al., 2004; Desilva et  al., 2007, 
2012). The striatum is known to be  selectively vulnerable to 
excitotoxicity at term, and this may suggest a potential neuronal 
response to locally increasing extracellular glutamate levels 
(Martin et  al., 1997a). In P6 rats, exposure to hypoxic 
preconditioning led to upregulation of Glt-1  in the cortex and 
suppression in the striatum, with no detectable changes in the 
hippocampus (Cimarosti et al., 2005). Glt-1 was also suppressed 
in the white matter in a preterm mouse model of chronic 
hypoxia, although this model was not subjected to ischemia 
and showed no sign of reactive astrogliosis (Raymond et  al., 
2011). Moreover, hypoxia has been found to alter the expression 
of Glt-1 splice variants in mouse brain and neurons of newborn 
pigs (Munch et  al., 2003; Pow et  al., 2004).
Exposure of mouse astrocytes, rat microglia, and human 
blood macrophages to the bacterial endotoxin lipopolysaccharide 
(LPS) and the pro-inflammatory cytokine TNFα has been found 
to enhance EAAT2 expression and glutamate uptake function 
in vitro (Rimaniol et  al., 2000; Persson et  al., 2005; O’Shea 
et al., 2006). On the other hand, TNFα suppresses both glutamate 
uptake and EAAT2  in a dose-dependent manner (via NF-κB) 
in human fetal astrocytes (Fine et  al., 1996; Liao and Chen, 
2001; Su et  al., 2003). TNFα also selectively suppresses EAAT2 
via NF-κB during hypoxia in vitro (Boycott et  al., 2008).
An important finding is that EAAT2 is upregulated in the 
reactive astrocytes and macrophages of post-mortem human 
brain tissue from preterm babies with white matter injury 
compared to controls, suggesting a possible response to hypoxia-
ischemia and/or inflammation in the preterm brain (Desilva 
et  al., 2008). Pre-oligodendrocytes in both cases and controls 
expressed EAAT2, with no qualitative differences in expression, 
although function was not measured. Upregulation of EAAT2 in 
reactive astrocytes and macrophages in preterm white matter 
injury may be an adaptive mechanism to counteract excitotoxicity, 
or it could be  a secondary mechanism due to gliosis. 
Whether in chronic white matter injury, this upregulation 
contributed to excitotoxicity via transport reversal remains to 
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be  established. Further studies are needed to elucidate how 
perinatal hypoxia-ischemia and infection/inflammation affect 
EAAT2 homeostasis, separately and in combination. Interestingly, 
genome-wide gene expression analysis of reactive astrocytes 
in two adult mouse models of ischemic stroke and LPS-induced 
neuroinflammation revealed that at least half of the altered 
gene expression is specific on the insult, with indication that 
reactive astrocytes may be  neuroprotective in ischemia but 
detrimental in neuroinflammation (Zamanian et  al., 2012). 
Overall, candidacy of EAAT2 is supported by the fact that 
dysregulation is implicated in several neurological, 
neurodegenerative, and psychiatric disorders thought to involve 
glutamate excitotoxicity (i.e., transient cerebral ischemia, 
ischemic stroke, epilepsy, traumatic brain injury, amyotrophic 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, chronic 
pain, Huntington’s disease, HIV-associated cognitive disorder, 
glioma, major depression, schizophrenia, and addiction) 
(Danbolt, 2001; Beart and O’Shea, 2007; Fontana, 2015;  
Karki et  al., 2015; Takahashi et  al., 2015; Verkhratsky et  al., 
2016; Zhang et  al., 2016; Zhou et  al., 2016; Goodwani et  al., 
2017; O’Donovan et al., 2017; Assefa et al., 2018; Fogarty, 2018; 
Kim et  al., 2018; Parkin et  al., 2018).
A better understanding of the role of glutamate transport 
in preterm brain injuries will require further investigations of 
EAAT1 in the cerebellum. EAAT1 is highly expressed in cerebellar 
astrocytes, particularly Bergmann’s glia (Lehre et  al., 1995; 
Danbolt, 2001). The processes of these cells ensheath the Purkinje 
cell synapses, which have been suggested to be  selectively 
vulnerable to excitotoxicity induced by hypoxia-ischemia (Harding 
et  al., 1984; Shibata et  al., 1996). Indeed, EAAT1 is 
developmentally upregulated from 23  weeks gestation, possibly 
in conjunction with the maturation of the Purkinje cells. 
Importantly, EAAT1 undergoes rapid changes in hypoxic-ischemic 
encephalopathy at term, with a decrease in the molecular layer 
and an increase in the Purkinje and inner granule cell layer 
at an early stage. This increase becomes marked at a later 
stage, potentially pointing to an adaptive neuroprotective 
mechanism against excitotoxicity (Inage et  al., 1998).
Mechanisms leading to loss of expression and/or function 
are likely to be  complex. Ying’s (1997) “deleterious network 
hypothesis” (1997) suggests that glutamate build-up may lead 
to detrimental vicious cycles. For example, receptor overactivation 
may lead to increased energy consumption and oxidative damage, 
which is known to impair glutamate transporters’ activity and 
expression, potentially leading to reverse transport with further 
glutamate release. Ion flux may cause cell swelling, leading to 
impaired energy metabolism (Danbolt, 2001). Inflammation 
may further potentiate the risks of excitotoxicity via glutamate 
transport suppression, including selective effects on EAAT2 
(Aden et  al., 2010; Kapitanovic Vidak et  al., 2012). Evidence 
to date supports the concept of suicide loops in 
pre-oligodendrocytes, which could provide both the source and 
the target for excitotoxic injury in the preterm brain. In this 
context, the combination of developmental upregulation of 
EAAT2 and establishment of reverse transport in the context 
of an energy failure could increase vulnerability of 
pre-oligodendrocytes to excitotoxic death (Back and Rosenberg, 
2014). Similarly, transient expression in neuronal populations 
could feed into suicide loops and explain the loss of layer V 
pyramidal neurons accompanying necrotic PVL (Andiman et al., 
2010). This is a different mechanism to that hypothesized in 
the mature brain, where the sources of glutamate killing neurons 
are thought to be other cells, including astrocytes and excitatory 
terminals (Lipton and Rosenberg, 1994) or, alternatively, 
retrograde degeneration from axonal injury. Astrocytes may 
have a delayed response due to their unique ability to use 
glycogen as a metabolic fuel during the initial stages of energy 
deprivation. In this scenario, extracellular glutamate 
concentrations may rise significantly only after depletion of 
glycogen stores in astrocytes (Grewer et  al., 2008), with a 
subsequent steep rise in extracellular glutamate and excitotoxic 
cell death (Gouix et  al., 2009). In chronic white matter injury, 
upregulation of astrocytic EAAT2 may be  detrimental when 
accompanied by establishment of reverse transport. Experimental 
data are needed to evaluate these hypotheses.
POTENTIAL FUTURE DEVELOPMENTS
In summary, it is plausible that both up- and downregulation 
of EAAT2 contribute to disease, depending on animal model, 
developmental stage, type and severity of the insult, and 
comorbidities. Regulation and dysregulation of EAAT2 may 
occur at the level of transcription (including epigenetic 
regulation), translation, trafficking, transport, and degradation 
(Karki et al., 2015; Takahashi et al., 2015). Accordingly, treatments 
aiming at restoring EAAT2 expression are a current area of 
research in neuroprotection, alongside enhancement of the 
transport function (Fontana, 2015). Ceftriaxone, a licensed 
β-lactam antibiotic safe and tolerable for humans, enhances 
EAAT2 expression and has been shown to be  neuroprotective 
in animal models of several adult excitotoxic disorders. Although 
no significant effects have been seen in clinical trials for 
amyotrophic lateral sclerosis and adult stroke, it is already 
widely used for the treatment of CNS infections in newborns 
and would therefore be a feasible drug to explore in the context 
of preterm neuroprotection. Guanosine enhances EAAT2 
transport function and has shown neuroprotective effects in 
rat models of hypoxic-ischemic encephalopathy (Moretto et al., 
2005, 2009) and adult cortical focal ischemia, via multiple 
mechanisms including prevention of free radical attack and 
pro-inflammatory response (Hansel et  al., 2014, 2015). Several 
other expression and function enhancers of EAAT2 are currently 
gathering attention as a potential therapeutic approach for a 
variety of adult disorders and await exploration in the context 
of the newborn brain (Fontana, 2015). It is currently unknown 
whether EAAT2 enhancers would restore glutamate uptake or 
exacerbate reverse transport in the preterm brain. Combination 
therapies targeting different mechanisms and therapeutic windows 
will also need exploring, including more established (i.e., 
magnesium sulfate) and more exploratory therapies (e.g., anti-
inflammatory treatment) (Ofek-Shlomai and Berger, 2014).
Genetic risk stratification and pharmacogenomic approaches 
focusing on interindividual differences in treatment response 
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are gathering interest and, as our healthcare systems develop, 
the integration of genomic data in clinical care seems an 
increasingly achievable goal (Rehm, 2017). Exploratory studies 
have implicated several functional genetic variants involved in 
glutamate excitotoxicity and inflammation in neurodevelopmental 
impairment, including as a sequelae of perinatal brain injuries 
(O’Callaghan et al., 2009, 2012, 2013; Wu et al., 2011; Kapitanovic 
Vidak et  al., 2012). Among these, common genetic variants 
altering EAAT2 expression have been reported in association 
with cerebral palsy and neurodevelopmental delay in very 
preterm newborns (Rajatileka et al., 2017). Replication in larger 
samples, genome-wide designs and comparison with term brain 
injuries are needed to consolidate and expand the finding. 
Identification of panels of genetic variants that collectively 
increase risk of injury may be  integrated with other types of 
clinical information and help identify high-risk pregnancies. 
Moreover, integration of genetic information has the potential 
to contribute to a more personalized approach to the care of 
the preterm newborn, with recent studies focusing on the 
interactions between genetic variants and responsiveness to 
antenatal magnesium sulfate therapy (Costantine et  al., 2012; 
Clark et  al., 2018). EAAT2 variants remain to be  evaluated 
in this context.
Future in vivo studies will need to explore whether 
dysregulation of the main glutamate transporter, EAAT2, is 
central to the pathogenesis of preterm brain injuries or if it 
is a secondary process and whether the different cellular effects 
represent destructive or compensatory mechanisms. As explained 
by Danbolt (2001), “as long as one variable is not extreme, 
it will be the combination of several factors that will determine 
whether the ship will sink,” and several different primary events/
changes may share a final common pathway. Well-designed 
animal model studies will be  needed to provide mechanistic 
evidence. Human post-mortem studies can provide insights 
into patterns of dysregulation of expression, function, and 
localization specific to the different types of perinatal brain 
injuries, though limited by confounding factors, post-mortem 
artifacts, reproducibility, and sample size. Promising preliminary 
findings on the neuroprotective effects of EAAT2 suggest that 
this is certainly an avenue worth exploring.
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